Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

Dementia patients with certain changes in their brain's white matter more likely to be apathetic

Dementia patients with a certain type of changes in their brain's white matter are more likely to be apathetic than those who do not have these changes, reveals a patient study carried out by the Sahlgrenska Academy and Sahlgrenska University Hospital.

3 Dec 2009

Research study compares genetic make-up of humans and primates

In spite of their genetic similarity to humans, chimpanzees and great apes have maximum lifespans that rarely exceed 50 years. The difference, explains USC Davis School of Gerontology Professor Caleb Finch, is that as humans evolved genes that enabled them to better adjust to levels of infection and inflammation and to the high cholesterol levels of their meat rich diets.

3 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

Accera Pharmaceuticals to implement the Veeva CRM suite of multi-tenant SaaS applications

Less than 9 months after implementing a new CRM application, Accera Pharmaceuticals began searching for a replacement. The commercial-stage biotechnology company, which launched Axona™ (a prescription-only medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease) around the same time as it implemented its current system, had quickly outgrown the generic CRM tool.

2 Dec 2009

A leader in the fight against brain diseases and in drug discovery joins UF

A leader in the fight against brain diseases and in drug discovery to help Alzheimer's patients has joined the University of Florida College of Medicine, interim dean Michael Good, M.D., announced.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

Human-animal bond offers significant benefits

A pet owner knows the enormous joy and comfort that an animal can provide, especially in troubled times. Most pets are considered important members of the family and irreplaceable companions.

1 Dec 2009

Glutamatergic nerve cells regularly generated in the brain

Until only a few years ago, neurogenesis - the process of nerve cell development - was considered to be impossible in the adult brain. The textbooks asserted that dead nerve cells could not be replaced. Then researchers discovered regions in the forebrain in humans in which new nerve cells can be generated throughout life. These so-called GABAergic cells use gamma-aminobutyric acid (GABA), a neurotransmitter of the central nervous system.

1 Dec 2009

Brain monitors help avoid postop dementia from routine anesthesia over-medication

To date, hospitals have not found a billing code that insurers will reimburse them for the $20 cost of the disposable sensor for your brain monitor for 'going under' for surgery.

1 Dec 2009

Americans living in the Southern region may have elevated risk of dying from stroke

The "stroke belt" has a tight hold. People born in the Southern stroke belt have a higher risk of dying from stroke as adults, even if they later move away, compared to people who were born in other parts of the country.

1 Dec 2009

Alzheimer's Association offers tips and round the clock assistance for caregivers during holiday season

In Massachusetts, approximately 70% of those with Alzheimer's disease are cared for at home, so the Alzheimer's Association is preparing for a surge in calls to its 24/7 Helpline during the holiday season. For most families, holidays are filled with opportunities for togetherness and sharing, but for a family dealing with Alzheimer's, holidays can also be stressful and filled with special challenges, according to the experts at the Alzheimer's Association.

30 Nov 2009

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.

30 Nov 2009

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.

27 Nov 2009

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer’s disease.

26 Nov 2009

Wnt signaling pathway plays a role in diabetic retinopathy

A group led by Dr. Jian-xing Ma at The University of Oklahoma Health Sciences Center, Oklahoma City, OK has demonstrated that the Wnt signaling pathway plays a role in diabetic retinopathy.

26 Nov 2009

Strategies to reduce greenhouse gases benefit human health, show new studies

Today, new studies published in the Lancet show that strategies to reduce greenhouse gases also benefit human health. The Lancet series highlights case studies on four climate change topics - household energy, transportation, electricity generation, and agricultural food production.

26 Nov 2009

Canadian Stroke Network receives $19.2M federal grant

The Canadian Stroke Network, one of Canada's Networks of Centres of Excellence, has received $19.2 million from the federal government over three years to support valuable research into stroke, one of the leading causes of death and disability in Canada.

26 Nov 2009

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AclarusDx Alzheimer’s test now available as RUO product

Dementia patients with certain changes in their brain's white matter more likely to be apathetic

Research study compares genetic make-up of humans and primates

FDA approves revised clinical trial protocol for CytRx' arimoclomol

Accera Pharmaceuticals to implement the Veeva CRM suite of multi-tenant SaaS applications

A leader in the fight against brain diseases and in drug discovery joins UF

DiaMedica to acquire all issued and outstanding shares of Sanomune

MRI pioneer honored with MRC Millennium Medal

Human-animal bond offers significant benefits

Glutamatergic nerve cells regularly generated in the brain

Brain monitors help avoid postop dementia from routine anesthesia over-medication

Americans living in the Southern region may have elevated risk of dying from stroke

Alzheimer's Association offers tips and round the clock assistance for caregivers during holiday season

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Wnt signaling pathway plays a role in diabetic retinopathy

Strategies to reduce greenhouse gases benefit human health, show new studies

Canadian Stroke Network receives $19.2M federal grant

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in